跳至主要内容
临床试验/NCT01627158
NCT01627158已完成1 期

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Double-dummy, Single Centre, Single Dose, Crossover Study in Healthy Subjects

Orion Corporation, Orion Pharma1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
72
试验地点
1
主要终点
Pharmacokinetic parameter Cmax of plasma formoterol concentration

研究概览

简要总结

The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent (IC) obtained.
  • Males and females, 18-60 (inclusive) years of age.

排除标准

  • Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
  • Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  • Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
  • Known hypersensitivity to the active substance(s) or the excipient of the drug.
  • Pregnant or lactating females.

研究组 & 干预措施

Budesonide/formoterol Easyhaler

Experimental

Budesonide/formoterol Easyhaler

干预措施: Budesonide/formoterol Easyhaler (Drug)

Symbicort Turbuhaler

Active Comparator

Symbicort Turbuhaler

干预措施: Symbicort Turbuhaler (Drug)

Charcoal and Budesonide/formoterol Easyhaler

Experimental

干预措施: Charcoal and Budesonide/formoterol Easyhaler (Drug)

Charcoal and Symbicort Turbuhaler

Active Comparator

干预措施: Charcoal and Symbicort Turbuhaler (Drug)

结局指标

主要结局

Pharmacokinetic parameter Cmax of plasma formoterol concentration

时间窗: 24 h

Pharmacokinetic parameter Cmax of plasma budesonide concentration

时间窗: within 12 h

Pharmacokinetic parameter AUCt of plasma budesonide concentration

时间窗: 12 h

Pharmacokinetic parameter AUCt of plasma formoterol concentration

时间窗: 24 h

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Pharmacokinetic Study Comparing... | 临床试验